SCHEDULE 13G/A: Biotechnology Value Funds Disclose Significant Stake in Forte Biosciences

Multiple Biotechnology Value Funds and affiliated entities, including Mark N. Lampert, have disclosed beneficial ownership of up to 9.99% of Forte Biosciences, Inc.'s common stock as of December 31, 2024.

Summary

• As of December 31, 2024, Biotechnology Value Fund, L.P. (BVF) beneficially owned 338,860 shares, representing approximately 5.3% of Forte Biosciences, Inc.'s outstanding common stock.
• Biotechnology Value Fund II, L.P. (BVF2) beneficially owned 262,365 shares, representing approximately 4.1% of the outstanding shares.
• Biotechnology Value Trading Fund OS LP (Trading Fund OS) beneficially owned 30,882 shares, representing approximately 0.5% of the outstanding shares.
• BVF GP Holdings LLC (BVF GPH) is deemed to beneficially own 601,225 shares, representing approximately 9.3% of the outstanding shares, through its control over BVF and BVF2 general partners.
• BVF Partners L.P. (Partners), BVF Inc., and Mark N. Lampert are each deemed to beneficially own 643,622 shares, representing approximately 9.99% of the outstanding shares, encompassing holdings across BVF, BVF2, Trading Fund OS, and a Partners managed account.
• The total number of shares outstanding used for percentage calculation was 6,393,323 as of December 30, 2024, plus 49,340 shares underlying certain Pre-Funded Warrants exercisable by the Reporting Persons.
• The Reporting Persons and a Partners managed account held an aggregate of 65,357 Pre-Funded Warrants, exercisable immediately at $0.001 per share, but limited by a 9.99% beneficial ownership blocker, allowing for the exercise of 49,340 shares as of December 31, 2024.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a specialized biotechnology investment fund is generally viewed positively, as it suggests a vote of confidence in the company's value proposition by an informed investor, even if the investment is passive.

Positives

• A significant stake by specialized biotechnology investment funds (Biotechnology Value Fund, L.P. and affiliates) may signal confidence in Forte Biosciences, Inc.'s long-term prospects and valuation.
• The investment is stated to be for passive purposes, not for changing or influencing control, which can be viewed as a stable, long-term investment by a reputable fund.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction, as it is solely a beneficial ownership disclosure.

Industry Context

This filing is a standard disclosure in the biotechnology sector, indicating that a specialized investment fund has taken or maintained a significant passive stake in Forte Biosciences. Such investments by dedicated biotech funds often reflect a belief in the underlying scientific or commercial potential of the company's pipeline or technology, aligning with broader trends of institutional interest in innovative life sciences companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake can influence market perception, potentially increasing investor confidence and liquidity for Forte Biosciences' stock.
• Investment Community: Provides transparency regarding the ownership structure and the presence of a notable biotechnology-focused fund among the company's largest shareholders.

Key Dates

Recommendation

Keywords

Forte Biosciences, Common Stock, SEC Filing, Schedule 13G, Beneficial Ownership, Biotechnology Value Fund, Mark N. Lampert, Investment, Equity Stake, Pre-Funded Warrants, Biotechnology